by Aras Rezvanian | Nov 30, 2018 | Niemann-Pick Type A |
Niemann-Pick Type A (NPA) affects about 1 in 250,000 individuals, with a higher frequency in individuals of Ashkenazi Jewish descent, where it’s about 1 in 40,000. NPA is caused by a mutation in the SMPD1 gene, a gene encoding acid sphingomyelinase which, when...
by Naz Dana | Nov 5, 2018 | Business |
In June, we launched Perlara On the Go, a monthly post updating you on upcoming events – be they conferences that Perlara team members are participating in, events that may be of interest to the life sciences community at large, or recaps of past events. Read on...
by Naz Dana | Oct 1, 2018 | Business |
In June, we launched Perlara On the Go, a monthly post updating you on upcoming events – be they conferences that Perlara team members are participating in, events that may be of interest to the life sciences community at large, or recaps of past events. Read on...
by Naz Dana | Sep 26, 2018 | Business |
Since the spring, our blog has featured regular posts introducing Perlara team members who weren’t a part of the founding team. From recent hires to a long-time team member, from two senior scientists to two research associates, we’ve covered almost...
by Sangeetha Iyer | Feb 6, 2018 | Niemann-Pick Type A |
In December of 2016, Perlara partnered with Wylder Nation to initiate an NPA PerlQuest, a research and drug discovery program for Niemann Pick Type A disease. If you’ve been following our blog, you’ve kept up with our fly team’s efforts in...
